Cancer Treatment Today

Cholangiocarcinoma is an aggressive malignancy with limited therapeutic options. There are limited small studies exp[loring the role of Vontrient in treating it, but the results are still preliminary and not accepted by the guidelines. There are ongoing studies of this drug in combination with trametinib in cholangiocarcinoma.

Shroff RT et al, The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.
Br J Cancer. 2017 May 23;116(11):1402-1407.